Barclays
KPTI icon

Barclays’s Karyopharm Therapeutics KPTI Stock Holding History

Barclays’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,400
Closed -$326K – 6947
2017
Q2 		$326K Buy
+2,400
New +$355K ﹤0.01% 3921

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Barclays's KPTI Position: Q1 2026 in Review

Barclays increased its Karyopharm Therapeutics (KPTI) stake by 81% in Q1 2026, buying an estimated $25.3K and bringing the position to 7,424 shares worth $41.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4385.

Barclays first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $11.1M in Q1 2023. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Barclays held 7,424 shares of Karyopharm Therapeutics worth $41.4K as of Q1 2026.
  • Barclays bought 3,315 Karyopharm Therapeutics shares in Q1 2026, an estimated $25.3K.
  • Karyopharm Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4385 holding.
  • Barclays first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • Barclays's Karyopharm Therapeutics position peaked at $11.1M in Q1 2023.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.